Ningetinib

DB16256InvestigationalSmall molecule

Ningetinib is under investigation in clinical trial NCT03758287 (Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative).

Mechanism: Pharmacologically active on Receptor-type tyrosine-protein kinase FLT3, Vascular endothelial growth factor receptor 2, and Hepatocyte growth factor receptor
Curator reviewed
Formula / weight: C₃₁H₂₉FN₄O₅ · 556.594 g/mol (avg)
Also known as: Ct-053 free base · Ct-053-ptsa free base · Ct053ptsa free base
Code names: CT053PTSA

Resolves to

Compound

UNIIPW3Q92Z6A4CAS1394820-69-9ChEMBLCHEMBL3984441

Structure

InChIKeyVQYYQSZNRVQLIS-UHFFFAOYSA-NSMILESCN1N(C(=O)C(C(=O)NC2=CC(F)=C(OC3=CC=NC4=C3C=CC(OCC(C)(C)O)=C4)C=C2)=C1C)C1=CC=CC=C1

Targets

P36888FLT3P35968KDRP08581METQ12866MERTKP30530AXL

What you can answer from here — as of June 15, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

15+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ningetinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account